Shots:
- Gilead Sciences has entered into a definitive agreement to acquire Arcellx, incl. anito-cel from their 2022 collaboration & Arcellx’s D-Domain CAR technology platform, for the implied equity value of $7.8B
- As per the deal, Gilead, which owns ~11.5% of Arcellx, will launch a tender offer for $115/share, plus a non-transferable CVR of $5/CVR tied to $6B cumulative anito-cel sales from launch till 2029, with remaining shares acquired later via a second-step merger; closing expected in 2026
- Also, the BLA for anito-cel as a 4L therapy in r/r multiple myeloma, supported by P-I & pivotal P-II (iMMagine1) data, was accepted by the US FDA with a PDUFA action date of Dec 23, 2026
Ref: Arcellx | Image: Arcellx | Press Release
Related News: Gilead Sciences to Acquire Repare Therapeutics’ Polθ ATPase Inhibitor RP-3467 for ~$30M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
